ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal [Yahoo! Finance]
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Yahoo! Finance
phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease (AD). The LIFT-AD study investigated once-daily fosgonimeton (40 mg) subcutaneous injection versus placebo over a treatment period of 26 weeks in mild-to-moderate AD patients. The study did not meet the primary endpoint which was the Global Statistical Test (GST), a combination of results from measures of cognition and function. The study also failed to meet the key secondary endpoints of changes in cognition and function, plasma biomarkers of neurodegeneration, protein pathology and neuroinflammation. Shares of Athira have increased 16.4% so far this year compared with the industry's growth of 0.6%. Image Source: Zacks Investment Research However, in pre-specified subgroups of patients with moderate AD or who are carriers of the APOE4 gene, cognition and function improved or stabilized in patients who received fosgonimeton compared to place
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena to Participate in Upcoming Healthcare ConferencesBusiness Wire
- A New Era For Alzheimer's Disease May Be Around The Corner [Forbes]Forbes
- What Makes Prothena (PRTA) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks [Yahoo! Finance]Yahoo! Finance
- Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $66.00 to $62.00. They now have an "outperform" rating on the stock.MarketBeat
PRTA
Earnings
- 8/8/24 - Beat
PRTA
Sec Filings
- 8/8/24 - Form S-8
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- PRTA's page on the SEC website